Equities
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)12.47
  • Today's Change-0.150 / -1.19%
  • Shares traded16.48m
  • 1 Year change+0.40%
  • Beta0.7310
Data delayed at least 15 minutes, as of Feb 13 2026 08:08 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

The United Laboratories International Holdings Limited is an investment holding company principally engaged in the sales of intermediate products, bulk medicine and finished products. The Company operates its business through three segments. The Intermediate Products segment is engaged in the sale of intermediate products. The Bulk Medicine segment is engaged in the sale of bulk medicine. The Finished Products segment is engaged in the sale of antibiotics finished products, non-antibiotics finished products and capsule casings. Through its subsidiaries, the Company is also engaged in the production and sale of organic fertilizer.

  • Revenue in HKD (TTM)15.95bn
  • Net income in HKD3.46bn
  • Incorporated--
  • Employees17.40k
  • Location
    United Laboratories International Holdings Ltd6 FuK Wang StreetYuen Long Industrial EstateYuen Long Hong KongHKG
  • Phone+852 26871033
  • Fax+852 26871031
  • Websitehttps://www.tul.com.cn/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Zai Lab Ltd3.45bn-1.62bn16.38bn1.87k--2.70--4.74-1.52-1.523.215.370.41193.196.53---19.29-33.80-27.61-39.1261.5264.07-46.83-186.772.68--0.2108--49.5998.3823.17--32.19--
Ascletis Pharma Inc2.67m-292.43m17.87bn208.00--7.68--6,683.74-0.2989-0.29890.00272.190.00110.266811.5911,573.89-12.10-8.46-12.73-8.8036.217.91-10,937.78-522.1214.53--0.0023---97.73-62.52-107.95---40.26--
Vigonvita Life Sciences Co Ltd-100.00bn-100.00bn18.10bn---------------------------------------------------94.07---1,848.73------
Ab&B Bio Tech Co Ltd JS366.15m-253.82m20.18bn583.00--530.23--55.12-0.6451-0.64510.93060.0968----------------67.29---69.32--0.3162-9.490.9646--397.65--39.09------
HUTCHMED (China) Ltd4.71bn3.65bn20.22bn1.78k5.542.105.394.304.184.185.3911.020.39667.093.862,599,556.0030.79-9.5540.72-13.7744.1539.8477.64-20.324.51--0.07---24.8025.20-62.56--15.93--
Sunshine Lake Pharma Co Ltd3.82bn-447.80m24.19bn6.53k--54.7420,257.626.34-0.7765-0.77656.620.7672------582,679.50--------73.62---12.86--0.7739-0.75910.5111---37.06---212.17------
The United Laboratories Intl. Hldgs Ltd.15.95bn3.46bn24.90bn17.40k6.621.305.981.561.911.918.789.690.53972.895.97938,145.0011.719.3717.4614.5447.2444.3321.7015.061.60--0.247226.010.138710.39-1.5432.8937.2545.96
Shanghai Henlius Biotech Inc6.56bn932.24m24.90bn3.54k41.9510.1517.653.801.721.7212.067.090.53861.735.861,865,468.007.66-3.2113.85-5.7675.7772.5014.22-7.870.504610.470.5185--6.11128.9850.26--10.83--
PegBio Co Ltd-100.00bn-100.00bn26.11bn58.00--89.25----------0.7479------------------------3.07--0.2439-------1.49------
Grand Pharmaceutical Group Ltd11.70bn2.08bn26.83bn12.44k12.721.5410.352.290.59430.59433.354.900.45573.663.88976,472.807.9910.4010.8114.2457.6461.0417.5322.800.9872--0.210729.1210.5912.0631.3016.490.739822.05
China Resources Pharmaceutical Group Ltd295.11bn3.19bn29.34bn86.00k9.190.51922.250.09940.50830.508346.978.990.94345.572.414,059,329.002.863.1410.2811.7815.8115.593.033.021.1211.260.424822.385.307.41-13.062.9512.427.30
Duality Biotherapeutics Inc2.45bn-3.20bn29.48bn191.00--8.74--12.01-36.93-36.9328.6737.42------14,438,690.00--------37.13---130.43------0.0228--8.66---193.82------
Simcere Pharmaceutical Group Ltd8.04bn995.43m31.88bn6.82k30.353.7122.873.970.40470.40473.263.310.58452.202.811,220,719.007.248.749.9312.4281.0078.5312.3915.601.574.720.145344.120.41485.672.57-6.098.48--
Xuanzhu Biopharmaceutical Co Ltd36.14m-629.22m33.93bn197.00--35.47--938.68-1.21-1.210.06981.85----------------41.02---1,740.97--1.10--0.0013--103,672.40---85.13------
Data as of Feb 13 2026. Currency figures normalised to United Laboratories International Holdings Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

10.05%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 07 Jan 202642.09m2.13%
Fullgoal Fund Management Co., Ltd.as of 30 Jun 202535.00m1.77%
Dimensional Fund Advisors LPas of 08 Jan 202623.90m1.21%
American Century Investment Management, Inc.as of 08 Jan 202622.63m1.15%
Norges Bank Investment Managementas of 30 Jun 202516.79m0.85%
BlackRock Fund Advisorsas of 09 Jan 202614.49m0.74%
China Universal Asset Management Co., Ltd.as of 30 Jun 202513.05m0.66%
ICBC UBS Asset Management Co. Ltd.as of 30 Jun 202512.88m0.65%
Victory Capital Management, Inc. (Investment Management)as of 31 Dec 20259.71m0.49%
Bosera Asset Management Co., Ltd.as of 30 Jun 20257.68m0.39%
More ▼
Data from 30 Jun 2025 - 05 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.